Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

mRNA COVID-19 vaccines induce high antibody titers with significant neutralizing potency in saliva

Scientists from the USA and Canada have recently demonstrated that the dynamics of antibody response induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (COVID-19) vaccines are different.

31 Aug 2021

Post-infection vaccination produces potent neutralizing antibodies against SARS-CoV-2 variants

The best protection against new SARS-CoV-2 infections or reinfections may be obtained by a combination of vaccine-elicited and infection-induced antibodies.

31 Aug 2021

J&J COVID-19 booster shot produces robust antibody response

The study showed neutralizing antibody responses produced by the Johnson & Johnson–Janssen vaccine was robust and stable eight months after immunization.

31 Aug 2021

The tale of mRNA vaccines: Turning calamity into opportunity

In a review paper published in the journal Nature Reviews, researchers from Carnegie Mellon University and the University of Pennsylvania have described the underlying technologies for mRNA vaccines and their future prospects with improved delivery systems and applications in diseases beyond the ongoing COVID-19 pandemic.

31 Aug 2021

Durability of cellular immune memory to SARS-CoV-2 after mRNA vaccination

A recent study, available on the bioRxiv* preprint server, investigated the durability of cellular immune memory after mRNA vaccination against SARS-CoV-2 and whether booster jabs affect the durability of different immune response components. The study included testing for antibodies and cellular immune responses in covid patients and recovered individuals.

31 Aug 2021

SARS-CoV-2 animal origin: What we know so far

Scientists at the University of Glasgow Centre for Virus Research in the United Kingdom and the South China Agricultural University in Guangzhou, China, have shed light on the animal origin of SARS-CoV-2, tracing back to the first outbreak of the severe acute respiratory syndrome coronavirus (SARS-CoV), the infectious agent of the severe acute respiratory syndrome (SARS) in China in 2002 to 2003.

31 Aug 2021

Scientists identify potential biomarkers to predict COVID-19 outcomes

A team of scientists from the United States has recently examined the trajectory of early immune biomarkers in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. They have identified specific plasma proteins that can accurately predict the clinical and virological outcomes in SARS-CoV-2 infected patients. The study is currently available on the medRxiv* preprint server.

31 Aug 2021

Vaccinated individuals with breakthrough SARS-CoV-2 infection have much lower risk of hospitalization

A recent study conducted by a team of US-based scientists has revealed that unvaccinated individuals are 17-times more likely to be hospitalized due to severe coronavirus disease 2019 (COVID-19) compared to those vaccinated against the disease. The study is currently available on the medRxiv* preprint server.

31 Aug 2021

Role of glycans on the SARS-CoV-2 spike protein in human receptor interaction

A team of investigators, led by Dr. Benjamin F. Mann, from Merck, USA have published a new study on the preprint server bioRxiv*. They have used a biochemical approach to control the glycosylation profile of the S protein receptor-binding domain (RBD) and to analyze the effect of different glycosylation patterns on receptor binding.

30 Aug 2021

Computational study identifies human proteins structurally similar to SARS-CoV-2 proteins

A new study published in Scientific Reports identifies the human proteins that share structural similarities with the SARS-CoV-2 proteins.

30 Aug 2021

Prevalence of vaccine breakthrough cases in SF Bay Area

A new study focuse on studying breakthrough infections in a highly vaccinated community owing to the emergence of SARS-CoV-2 variants.

30 Aug 2021

Will mRNA vaccine boosters be required for SARS-CoV-2 variants?

A new study shows that the highly effective mRNA Moderna vaccine designed against the original SARS-CoV-2 strain may lose some efficacy as new variants arise.

30 Aug 2021

Sustained and effective response to Janssen COVID-19 vaccine Is enhanced by delayed booster

A new study adds to the data on the optimum interval between the first and second doses of the adenovirus vectored COVID-19 vaccine.

30 Aug 2021

Can SARS-CoV-2 be transmitted in the food cold chain?

A new study reports that the risk of transmitting SARS-CoV-2 through such fomites is very low.

30 Aug 2021

Post mRNA-1273 vaccination rashes

A group of researchers reported that skin reactions after the administration of the mRNA-1273 vaccine are rare yet possible.

30 Aug 2021

Development of extra protective broad-spectrum antimicrobial face shield

In a new study available on the preprint server Preprints*, researchers have innovated a transparent face shield with intrinsic antimicrobial activity.

30 Aug 2021

Could genetic variants in host cell receptors (ACE2) explain COVID-19 susceptibility among certain ethnic groups?

Led by Ioannis Karakikes of Stanford University, a new study suggests some hospitalized patients with COVID-19 contain ACE2 genetic variants that increase ACE2 expression. Some variants that altered ACE2 protein expression and binding affinity were more prevalent in people with European backgrounds.

30 Aug 2021

Study reveals how SARS-CoV-2 variants of concern modulate receptor and antibody binding

In a trailblazing engineering effort, Canadian and US researchers indicate that the emergence of novel variants of SARS-CoV-2 stems from the mutations of spike glycoprotein that confer either increased affinity for the host cell receptor or increased antibody evasion.

30 Aug 2021

CoronaVac elicits lower antibody response than natural SARS-CoV-2 infection, study suggests

A recent study from Thailand highlights a rather low degree of neutralization-afforded protection mounted by the inactivated whole-virus CoronaVac vaccine compared to natural infection with SARS-CoV-2 – the virus that causes COVID-19.

30 Aug 2021

The impact of mild SARS-CoV-2 infection on maternal-fetal immunity

Recently, a new study published on the pre-print server bioRxiv* examined the effect that maternal asymptomatic COVID-19 had on decidual and peripheral immune cells during the later stage of pregnancy.

30 Aug 2021

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

mRNA COVID-19 vaccines induce high antibody titers with significant neutralizing potency in saliva

Post-infection vaccination produces potent neutralizing antibodies against SARS-CoV-2 variants

J&J COVID-19 booster shot produces robust antibody response

The tale of mRNA vaccines: Turning calamity into opportunity

Durability of cellular immune memory to SARS-CoV-2 after mRNA vaccination

SARS-CoV-2 animal origin: What we know so far

Scientists identify potential biomarkers to predict COVID-19 outcomes

Vaccinated individuals with breakthrough SARS-CoV-2 infection have much lower risk of hospitalization

Role of glycans on the SARS-CoV-2 spike protein in human receptor interaction

Computational study identifies human proteins structurally similar to SARS-CoV-2 proteins

Prevalence of vaccine breakthrough cases in SF Bay Area

Will mRNA vaccine boosters be required for SARS-CoV-2 variants?

Sustained and effective response to Janssen COVID-19 vaccine Is enhanced by delayed booster

Can SARS-CoV-2 be transmitted in the food cold chain?

Post mRNA-1273 vaccination rashes

Development of extra protective broad-spectrum antimicrobial face shield

Could genetic variants in host cell receptors (ACE2) explain COVID-19 susceptibility among certain ethnic groups?

Study reveals how SARS-CoV-2 variants of concern modulate receptor and antibody binding

CoronaVac elicits lower antibody response than natural SARS-CoV-2 infection, study suggests

The impact of mild SARS-CoV-2 infection on maternal-fetal immunity

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Severe Acute Respiratory Syndrome News and Research

Latest Severe Acute Respiratory Syndrome News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in